ORIC Pharmaceuticals, Inc. (ORIC) Deep Dive Video

Summary

Oric is a cash-rich, pre-revenue oncology biotech offering asymmetric upside if rinzimetostat’s safety edge and enozertinib’s brain-penetrant profile translate into pivotal clinical success.

View ORIC stock page · Read the ORIC research report

Loading the video player…